Dublin/Boston: Elan, along with its product partner Biogen, has reported another increase in instances of rare brain disease PML among users of its headline multiple sclerosis/Crohn’s disease treatment Tysabri.
Thu, 16 Sep, 2010 - 01:00
The monthly update showed two more cases in August, bringing total PML cases to 68.